Dysbiosis of the Gut Microbiome is associated with Tumor Biomarkers in Lung Cancer.
16SrRNAsequencing
Carcinoembryonic antigen
Cytokeratin 19 fragment
Fecal
Gut microbiome
Lung cancer
Neuron specific enolase
Journal
International journal of biological sciences
ISSN: 1449-2288
Titre abrégé: Int J Biol Sci
Pays: Australia
ID NLM: 101235568
Informations de publication
Date de publication:
2019
2019
Historique:
received:
23
04
2019
accepted:
18
07
2019
entrez:
10
10
2019
pubmed:
9
10
2019
medline:
19
5
2020
Statut:
epublish
Résumé
Lung cancer is a malignancy with high morbidity and mortality worldwide. More evidences indicated that gut microbiome plays an important role in the carcinogenesis and progression of cancers by metabolism, inflammation and immune response. However, the study about the characterizations of gut microbiome in lung cancer is limited. In this study, the fecal samples were collected from 16 healthy individuals and 30 lung cancer patients who were divided into 3 groups based on different tumor biomarkers (cytokeratin 19 fragment, neuron specific enolase and carcinoembryonic antigen, respectively) and were analyzed using 16S rRNA gene amplicon sequencing. Each lung cancer group has characterized gut microbial community and presents an elimination, low-density, and loss of bacterial diversity microbial ecosystem compared to that of the healthy control. The microbiome structures in family and genera levels are more complex and significantly varied from each group presenting more different and special pathogen microbiome such as
Identifiants
pubmed: 31595156
doi: 10.7150/ijbs.35980
pii: ijbsv15p2381
pmc: PMC6775324
doi:
Substances chimiques
Biomarkers, Tumor
0
RNA, Ribosomal, 16S
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2381-2392Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
Front Immunol. 2019 Feb 20;10:282
pubmed: 30842777
Science. 2018 May 25;360(6391):
pubmed: 29798856
J Nutr Biochem. 2018 Jul;57:246-254
pubmed: 29800811
Am Soc Clin Oncol Educ Book. 2019 Jan;39:531-542
pubmed: 31099633
Environ Microbiol. 2016 Jul;18(7):2272-86
pubmed: 27243236
Eur J Surg Oncol. 2017 Dec;43(12):2308-2314
pubmed: 28964610
Ann Oncol. 2018 Jun 1;29(6):1437-1444
pubmed: 29617710
Sci Rep. 2019 Jan 22;9(1):287
pubmed: 30670726
Elife. 2018 Jun 19;7:
pubmed: 29916366
Immunology. 2017 Aug;151(4):363-374
pubmed: 28542929
Microbiome. 2019 Jan 4;7(1):2
pubmed: 30609941
Cancer Cell. 2018 Apr 9;33(4):570-580
pubmed: 29634945
Crit Rev Microbiol. 2017 Feb;43(1):81-95
pubmed: 27781554
Lung Cancer. 2016 Dec;102:89-95
pubmed: 27987594
Nat Microbiol. 2019 Feb;4(2):293-305
pubmed: 30531976
Case Rep Gastroenterol. 2016 Dec 13;10(3):769-774
pubmed: 28100999
Bioinformatics. 2011 Nov 1;27(21):2957-63
pubmed: 21903629
Front Microbiol. 2017 Jun 30;8:1221
pubmed: 28713349
Front Microbiol. 2018 Feb 21;9:151
pubmed: 29515527
PLoS One. 2013;8(1):e53653
pubmed: 23335968
Allergol Int. 2017 Oct;66(4):523-528
pubmed: 28693971
Nat Rev Microbiol. 2017 Jan;15(1):55-63
pubmed: 27694885
Dis Markers. 2018 Oct 1;2018:2082840
pubmed: 30364165
Nat Rev Gastroenterol Hepatol. 2016 Dec;13(12):691-706
pubmed: 27848961
New Microbes New Infect. 2017 May 27;19:34-37
pubmed: 28702200
Science. 2015 Nov 27;350(6264):1079-84
pubmed: 26541610
Nucleic Acids Res. 2008 Jan;36(Database issue):D480-4
pubmed: 18077471
Nat Biotechnol. 2013 Sep;31(9):814-21
pubmed: 23975157
mSystems. 2017 Sep 26;2(5):null
pubmed: 28951889
Semin Immunol. 2017 Aug;32:25-34
pubmed: 28822617
Nat Methods. 2010 May;7(5):335-6
pubmed: 20383131
Ther Adv Med Oncol. 2018 Apr 11;10:1758835918763493
pubmed: 29662547
J Cell Biochem. 2019 Jan;120(1):105-114
pubmed: 30216488
J Med Microbiol. 2016 Dec;65(12):1347-1362
pubmed: 27902422
Immunol Rev. 2017 Jul;278(1):277-295
pubmed: 28658542
ISME J. 2018 Jun;12(7):1631-1641
pubmed: 29434315